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Valorisation-addendum
Valorisation in scientific research describes the value added to the society. Besides 
education and scientific research, valorisation is one of the key tasks of universities. 
As such, it is important to explicitly state the added value of the research performed.
1 Social and economic relevance?
Clinical trials in patients with immune-mediated neuropathies like Guillain-Barré 
syndrome (GBS), chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), 
and monoclonal gammopathy of undetermined significance related neuropathy 
(MGUSP) often used different outcome measures to present their results. In the past, 
multiple types of often ordinal outcome measures have been used in these disorders 
leading to different results of studies. The design and validation process of creating an 
outcome measure is a time consuming process with a burden to patients (they have 
to complete the same outcome measure several times) and with considerable costs. 
Furthermore, in order to obtain comparability between trials, researchers should strive 
to use the same existing outcome measures.
Proper attention should be given to the choice of the best outcome measure, 
particularly choosing outcome measures that have been tested in terms of their 
clinimetric properties in the disease of interest. The use of insensitive outcome 
measures might be the reason for trials in the inflammatory neuropathy field being 
negative. This could mean that the Food and Drug Administration (FDA), due to the 
use of improper outcome measures, is not approving treatments that might have an 
effect, which may hurt patients. 
Most outcome measures used thus far in inflammatory neuropathies are at the 
ordinal level and based on the classical test theory. The Rasch model overcomes the 
disadvantages of ordinal-based outcome measures. We constructed new outcome 
measures and evaluation new and existing outcome measures using the Rasch method. 
These outcome measures could overcome the previously presented problems. 
In addition, trial results evaluating treatment options are often driven by the presence 
or absence of having a significant (p-value) difference between the various (e.g. treated 
versus placebo) groups. However, the presence of a statistical significant difference 
does not always mean that the findings are clinically relevant. The minimum clinically 
important difference (MCID) was introduced in the current thesis as the minimum 
change in score necessary to reflect a clinically relevant change.[1] There are several 
methods available to calculate the MCID, thus showing its many faces and the lack of 
international consensus on this matter.[2] The biggest disadvantages of applying these 
MCID techniques is perhaps the standard error (SE) being considered “static (unchanged)” 
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throughout the range of the outcome measure being used. The MCID-SE concept using 
Rasch-transformed demonstrates a dynamic pattern of ‘being-a-responder’ in patients 
with immune-mediated neuropathies. SE values are the lowest in the middle part of the 
metric and increases towards the edges of the metric’s range. A responder is defined if a 
patient showed a significant change exceeding MCID-SE ≥ 1.96. 
Using the concept of MCID and responsiveness at the individual level could give 
physicians the opportunity to determine scientifically and objectively whether the 
patient is a responder or not. When the patient is not responding, one may consider 
to discontinue the treatment or to change to different treatment options. This would 
contribute to personalized medicine and could, at the same time, lower the costs in 
health care.
2 target groups 
Outcome measures are usually developed using the Classical Test Theory (CTT). 
However, outcome measures based on CTT may constitute items that are arbitrarily 
collected with ordinal response options (e.g. 0 never, 1 seldom, 2 quite often, 3 very 
often, 4 always).
Although the distance between the different response options appear linear (score 
1,2,3,4) is the true distance between the different categories not know and most 
probably unequal. Physicians often consider as an example a 1-point response change 
for an item (e.g., from 0 to 1) equivalent to a 1-point change from 2 to 3. 
Also, patients are requested to complete all items, even though some may be 
irrelevant or inappropriate for their level of ability. A sumscore of the scale’s items 
is often calculated and the obtained data generally treated as if they were linear; 
frequently being exposed to parametric analyses. Creating a sum of the item scores 
also assumes equal relevance (“weight”) of each item, which is highly unlikely. Based 
on these shortcomings, CTT-based outcome measures may limit the comparison of 
patients and study results.
Considering the shortcomings of the CTT, it is clear that a modern scientific approach 
is needed for the evaluation and construction of outcome measures to improve the 
findings in interventional trials. Using interval measures instead of ordinal scores would 
give a true reflection of disease impact, of differences between individuals and groups, 
and of treatment effects. One of the widely used approaches is the Rasch method, 
which was introduced by the Danish mathematician Georg Rasch. The Rasch model 
states that the probability of a patient being able to “correctly answer or complete” 
an item or task is a logistic function of the difficulty of the task and the ability of the 
patient to accomplish it. Rasch analysis transforms obtained ordinal scores into interval 
measures and places both items and patients’ parameter estimates on the same 
logodds units (logit) scale. Therefore a less affected patient (a patient with a higher 
ability) will have a greater chance to complete a more difficult item when compared 
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to a patient that is more disabled. In order to create an interval outcome measure 
using the Rasch model, several criteria have to be fulfilled. RUMM2030 is a computer 
program that ‘checks’ whether the raw data fulfil all these criteria. There are several 
ways to deal with items deviating from the models’ expectations. 
We have used a modern scientific approach, based on the Rasch model, leading to 
disease-specific, true interval measurement, and therefore enable highly improved 
evaluation and construction of outcome measures in interventional trials. There are 
several pharmaceutical companies, like Baxter, Talecris, Octapharma that are involved 
in development of immunomodulating therapy. Although creating outcome measures 
using the Rasch model is not novel, the outcome measures developed by our group 
are unique and novel. The advantages are that we provide an interval outcome 
measure for specific diseases. Moreover, using these outcome measures provides the 
opportunity to compare the results of different research or trials on the same linear 
ruler, thereby improving comparability of different studies. 
Muscle strength testing is frequently used in clinical trials as a primary outcome 
measure at the impairment level and can be measured using a tool like the Marin 
Vigorimeter [3] or by manual muscle testing (Medical Research Council (MRC) 
grades.[4] The MRC is the most widely applied tool to manually measure strength of 
muscle groups at bedside.[5] We demonstrated that physicians, independent of their 
experience or the type of neuromuscular illness examined, are unable to apply the 
MRC grades in a proper manner.[6] Also, the MRC grading system failed to differentiate 
various degrees of muscle weakness. In order to solve these problems, the MRC grades 
were modified to a homogenous four category response options. The four response 
categories are still ordinal based; therefore meaningful sum scores can only be made 
after transforming the data through Rasch. After Rasch modelling, we were able to 
present a transformed modified MRC 12 muscle groups summed score for GBS and 
CIDP. The Vigorimeter demonstrated the ability to capture clinically meaningful 
changes quite early in the interventional phase when compared with the primary 
ordinal-based outcome measure used.[7, 8] 
Although the MRC grading system is widely used, it holds several disadvantages. 
The Vigorimeter overcomes these advantages, however this tool only measures grip 
strength. These results might trigger companies to develop devices to measure 
strength at the interval levels. These devices should be, easy applicable, validated and 
not too expensive. Such a tool could also be used in clinical practice for the follow-up 
of patients. 
3 Activities and products
Creating and (re)analyse outcome measures to develop a Rasch-based tool at the 
interval level is a time-consuming and labour-intensive process, that warrants specific 
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expertise. The industry may prefer to buy our Rasch-build outcome measures rather 
than developing it themselves. Through paid licensing, we can offer companies (and 
other academia) our developed Rasch-build outcome measures including the required 
analysis key. Analysing the results obtained from Rasch-build outcome measures 
requires expertise. It takes several years before that expertise is obtained, and therefore 
we are able to offer this service to companies and other universities. 
4 Innovation
Existing tools for generating outcome measures are usually based on Classical Test 
Theory (CTT). CTT method holds several disadvantages, thereby creating an illusion of 
interval measurement. Therefore, CTT-based outcome measures limit the comparison 
of patients and study results. We have used a modern scientific approach, based on 
the Rasch model, leading to disease-specific, true interval measurement, and therefore 
highly improved evaluation and construction of outcome measures in interventional 
trials. Creating outcome measures using the Rasch model is not novel. However, the 
outcome measures developed by our group are unique and novel. The advantages are 
that we provide an interval outcome measure for specific diseases that are validated 
and responsive. Moreover, using these outcome measures provides the opportunity 
to compare the results of different research or trials on the same linear ruler, thereby 
improving comparability of different studies.
5 Implementation
We offer our outcome measures for use to companies and academia, through paid 
licensing. Moreover, we are able to perform the required analysis of the obtained data. 
These tools are intended to be used in clinical trials. For obtaining a license, please 
contact dr. Ingemar S.J. Merkies or prof.dr. C.G. Faber.
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